Cancer and Leukemia Group B: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Cancer and Leukemia Group B}} | |||
==Overview== | == Overview == | ||
Cancer and Leukemia Group B | [[File:Calgb_logo.gif|thumb|right|Logo of the Cancer and Leukemia Group B]] | ||
The '''Cancer and Leukemia Group B''' (CALGB) is a cooperative clinical trials group in the United States that focuses on research in the treatment of [[cancer]] and [[leukemia]]. It is part of the [[National Cancer Institute]]'s National Clinical Trials Network. The group conducts large-scale clinical trials to evaluate new treatments and improve existing therapies for various types of cancer. | |||
==History== | == History == | ||
The CALGB was established in 1956 as a collaborative effort among leading cancer research institutions. Its mission is to reduce the morbidity and mortality of cancer through innovative clinical research. Over the years, the group has contributed significantly to the advancement of cancer treatment protocols and has been involved in numerous landmark studies. | |||
== Structure == | |||
The CALGB is composed of a network of academic and community-based institutions across the United States. It includes a wide range of specialists, including [[oncologists]], [[hematologists]], [[surgeons]], [[radiologists]], and [[pathologists]]. The group is governed by a board of directors and operates through various committees that focus on specific types of cancer and research areas. | |||
==Research | == Research Focus == | ||
CALGB | The primary focus of the CALGB is to conduct clinical trials that test new therapies for cancer and leukemia. These trials are designed to evaluate the safety and efficacy of new drugs, combinations of drugs, and other treatment modalities. The group also investigates the biological mechanisms of cancer to identify potential targets for therapy. | ||
== Achievements == | |||
The CALGB has been instrumental in the development of several important cancer treatments. It has conducted pivotal trials that have led to the approval of new drugs and treatment regimens. The group's research has also contributed to the understanding of cancer biology and the development of personalized medicine approaches. | |||
==Collaboration | == Collaboration == | ||
The | The CALGB collaborates with other cooperative groups, research institutions, and pharmaceutical companies to enhance the scope and impact of its research. It is part of the Alliance for Clinical Trials in Oncology, which was formed by the merger of CALGB, the North Central Cancer Treatment Group, and the American College of Surgeons Oncology Group. | ||
== Related pages == | |||
* [[National Cancer Institute]] | |||
== | |||
* [[Clinical trial]] | * [[Clinical trial]] | ||
* [[Oncology]] | * [[Oncology]] | ||
* [[Leukemia]] | * [[Leukemia]] | ||
* [[ | * [[Cancer research]] | ||
[[Category:Cancer organizations]] | [[Category:Cancer organizations]] | ||
[[Category:Medical research | [[Category:Medical research organizations in the United States]] | ||
[[Category: | [[Category:Clinical trial organizations]] | ||
Latest revision as of 05:31, 16 February 2025
Overview[edit]
The Cancer and Leukemia Group B (CALGB) is a cooperative clinical trials group in the United States that focuses on research in the treatment of cancer and leukemia. It is part of the National Cancer Institute's National Clinical Trials Network. The group conducts large-scale clinical trials to evaluate new treatments and improve existing therapies for various types of cancer.
History[edit]
The CALGB was established in 1956 as a collaborative effort among leading cancer research institutions. Its mission is to reduce the morbidity and mortality of cancer through innovative clinical research. Over the years, the group has contributed significantly to the advancement of cancer treatment protocols and has been involved in numerous landmark studies.
Structure[edit]
The CALGB is composed of a network of academic and community-based institutions across the United States. It includes a wide range of specialists, including oncologists, hematologists, surgeons, radiologists, and pathologists. The group is governed by a board of directors and operates through various committees that focus on specific types of cancer and research areas.
Research Focus[edit]
The primary focus of the CALGB is to conduct clinical trials that test new therapies for cancer and leukemia. These trials are designed to evaluate the safety and efficacy of new drugs, combinations of drugs, and other treatment modalities. The group also investigates the biological mechanisms of cancer to identify potential targets for therapy.
Achievements[edit]
The CALGB has been instrumental in the development of several important cancer treatments. It has conducted pivotal trials that have led to the approval of new drugs and treatment regimens. The group's research has also contributed to the understanding of cancer biology and the development of personalized medicine approaches.
Collaboration[edit]
The CALGB collaborates with other cooperative groups, research institutions, and pharmaceutical companies to enhance the scope and impact of its research. It is part of the Alliance for Clinical Trials in Oncology, which was formed by the merger of CALGB, the North Central Cancer Treatment Group, and the American College of Surgeons Oncology Group.
